Uptake of pneumococcal polysaccharide vaccine in at-risk populations in England and Wales 1999–2005
RG Pebody, J Hippisley-Cox, S Harcourt… - Epidemiology & …, 2008 - cambridge.org
The UK has had a pneumococcal polysaccharide vaccination (PPV) programme for groups
at higher risk of invasive disease since 1992. This paper presents data from a sample of …
at higher risk of invasive disease since 1992. This paper presents data from a sample of …
Pneumococcal polysaccharide vaccine uptake in England, 1989–2003, prior to the introduction of a vaccination programme for older adults
K Noakes, RG Pebody, U Gungabissoon… - Journal of Public …, 2006 - academic.oup.com
Objective Following the licensure of 23-valent pneumococcal polysaccharide vaccine
(23vPPV) in 1989, a risk-group–only immunization policy was implemented in 1992 in …
(23vPPV) in 1989, a risk-group–only immunization policy was implemented in 1992 in …
Failure to vaccinate or failure of vaccine? Effectiveness of the 23-valent pneumococcal polysaccharide vaccine program in Indigenous adults in the Northern Territory …
S Moberley, V Krause, H Cook, K Mulholland… - Vaccine, 2010 - Elsevier
Over the last decade, there has been no discernible reduction in Invasive Pneumococcal
Disease (IPD) amongst Indigenous adults in the Northern Territory (NT) of Australia, despite …
Disease (IPD) amongst Indigenous adults in the Northern Territory (NT) of Australia, despite …
Predictors of pneumococcal vaccination among Australian adults at high risk of pneumococcal disease
Abstract Background Although nearly all Australian children are vaccinated against
pneumococcal disease, pneumococcal vaccine uptake is low among high-risk adults. This …
pneumococcal disease, pneumococcal vaccine uptake is low among high-risk adults. This …
Trends in incidence of pneumococcal disease before introduction of conjugate vaccine: South West England, 1996–2005
Introduction of pneumococcal conjugate and polysaccharide vaccines into the United
Kingdom's routine immunization programmes is expected to change the epidemiology of …
Kingdom's routine immunization programmes is expected to change the epidemiology of …
[HTML][HTML] Increased invasive pneumococcal disease, North east England, UK
C Houseman, GJ Hughes, KE Chapman… - Emerging infectious …, 2017 - ncbi.nlm.nih.gov
Since April 2014, invasive pneumococcal disease incidence has increased substantially
across North East England, United Kingdom, reversing the decline that followed the 2006 …
across North East England, United Kingdom, reversing the decline that followed the 2006 …
[HTML][HTML] Repeat pneumococcal polysaccharide vaccine in Indigenous Australian adults is associated with decreased immune responsiveness
S Moberley, PV Licciardi, A Balloch, R Andrews… - Vaccine, 2017 - Elsevier
Background Indigenous adults residing in the Northern Territory of Australia experience
elevated rates of invasive pneumococcal disease despite the routine use of 23-valent …
elevated rates of invasive pneumococcal disease despite the routine use of 23-valent …
[HTML][HTML] Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in people aged 65 years and over in the North …
LB Wright, GJ Hughes, KE Chapman, R Gorton… - Trials in …, 2013 - Elsevier
The 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for all
aged⩾ 65 years in the UK to help reduce the burden of invasive pneumococcal disease …
aged⩾ 65 years in the UK to help reduce the burden of invasive pneumococcal disease …
[HTML][HTML] The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004
JD Mooney, A Weir, J McMenamin, LD Ritchie… - BMC infectious …, 2008 - Springer
Abstract Background For winter 2003/2004 in Scotland, it was recommended that all those
aged 65 and over be eligible to receive 23-valent polysaccharide pneumococcal vaccine …
aged 65 and over be eligible to receive 23-valent polysaccharide pneumococcal vaccine …
[HTML][HTML] Pneumococcal vaccine coverage among individuals aged 18 to 64 years old with underlying medical conditions in the UK: a retrospective database analysis
I Matthews, X Lu, Q Xia, W Black, B Nozad - BMC public health, 2020 - Springer
Background In the UK certain groups with pre-disposing conditions are eligible for
vaccination with the pneumococcal polysaccharide vaccine (PPV23). Uptake of the vaccine …
vaccination with the pneumococcal polysaccharide vaccine (PPV23). Uptake of the vaccine …